Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes

Chemotherapy

Volumn 57, Issue 1, 2011, Pages 71-76

  Mao, Weidong ^a,b   Guan, Xunxing ^b   Tucker, Steven ^c   Li, Fengyan ^b   He, Zhenyu ^b   Wang, Junjie ^b   Guo, Jun ^b   Wu, Shangang ^b  

^a JIANGYIN PEOPLE S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c Pacific Cancer Centre   (Singapore)

Author keywords

Advanced breast cancer; Capecitabine; Second line chemotherapy; Vinorelbine

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; NAVELBINE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; MORNING DOSAGE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; TAXOIDS; VINBLASTINE;

EID: 79551522272     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321489     Document Type: Article

References (34)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150. (Pubitemid 46655601)
2. Vici P, Di Lauro L, Sergi D, Foggi P, Viola G, Mottolese M, Giotta F, Fattoruso SI, Corsetti S, Giannarelli D, Botti C, Lopez M: A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. Oncology 2008;75:175-181.
3. Crown J: Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 2001;6(suppl 3):17-21.
4. Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
5. Vici P, Belli F, Di Lauro L, Amodio A, Conti F, Foggi P, Gionfra T, Morelli MF, Botti C, Ferraironi A, Lopez M: Docetaxel in patients with anthracycline-resistant advanced breast cancer. Oncology 2001;60:60-65. (Pubitemid 32041433)
6. Valero V, Hortobagyi GN: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 2003;21:959-962.
7. Somali I, Alacacioglu A, Tarhan MO, Meydan N, Erten C, Usalp S, Yilmaz U: Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy 2009;55:155-160.
8. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-1252. (Pubitemid 23199126)
9. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P, Marty M: Efficacy and tolerance of vinorelbine and fluorouracil combination as firstline chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 1996;14:3097-104. (Pubitemid 26408802)
10. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L: Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 2000;18:3370-3377.
11. Saif MW, Katirtzoglou NA, Syrigos KN: Capecitabine: an overview of the side effects and their management. Anticancer Drugs 2008;19:447-464. (Pubitemid 351556397)
12. Walko CM, Lindley C: Capecitabine: a review. Clin Ther 2005;27:23-44. (Pubitemid 40347299)
13. Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S, Kinki Breast Cancer Study Group: Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 2010;56:166-170.
14. Sawada N, Fujimoto-Ouchi F, Ishikawa T, Tanaka Y, Ishitsuka H: Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models (abstract 5388). Proc Am Assoc Cancer Res 2002;43:1088.
15. Hess D, Thürlimann B, Pagani O, Aebi S, Rauch D, Ballabeni P, Rufener B, Castiglione- Gertsch M, Goldhirsch A, Swiss Group of Clinical Cancer Research (SAKK): Capecitabine and vinorelbine in elderly patients (> or=65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 2004;15:1760-1765.
16. Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U: Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005;16:64-69. (Pubitemid 40124480)
17. Ahn JH, Kim SB, Kim TW, Ahn SH, Kim SM, Park JM, Lee JS, Kang YK, Kim WK: Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 2004;19:547-553.
18. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger H, Brown CS, Tom Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493. (Pubitemid 29075232)
19. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
20. Morabito A, Filippelli G, Palmeri S, Cascinu S, FerraùF, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G: The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. Breast Cancer Res Treat 2003;78:29-36. (Pubitemid 36223014)
21. Ardavanis A, Kountourakis P, Maliou S, Vassilakopoulou M, Basioukas S, Kyriakou F, Koumna S, Rigatos G: Gemcitabine and oral vinorelbine as salvage treatment in patients with advanced anthracycline- and taxane-pretreated breast cancer. Anticancer Res 2007;27:2989-2992. (Pubitemid 47228033)
22. Onyenadum A, Gogas H, Markopoulos C, Bafaloukos D, Aravantinos G, Mantzourani M, Koutras A, Tzorakoelefterakis E, Xiros N, Makatsoris T, Fountzilas G, Kalofonos HP: Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. J Chemother 2007;19:582-589. (Pubitemid 350177970)
23. Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V: Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 2010;65:755-763.
24. Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, Peck R, Thomas E: Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008;8:234-241. (Pubitemid 351962144)
25. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborn CK, Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-3063. (Pubitemid 29470633)
26. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52.
27. Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD, Duffy MJ, Higgins NO: CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 2006;6:220.
28. Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Williston Park) 1997;11:43-48.
29. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD: Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-2326. (Pubitemid 34441659)
30. Finek J, Holubec L Jr, Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, Sediva M, Filip S, Kozevnikova R, Kormunda S: A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 2009;29:667-670.
31. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N, Villanova G: Alloral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial. Br J Cancer 2009;101:232-237.
32. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115. (Pubitemid 27021524)
33. Findlay M, von Minckwitz G, Wardley A: Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008;19:212-222. (Pubitemid 351201700)
34. Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56-66.